HER2 Is Frequently Over-expressed in Ovarian Clear Cell Adenocarcinoma : Possible Novel Treatment Modality Using Recombinant Monoclonal Antibody against HER2, Trastuzumab

• FUJIMURA Masaki

  Department of Obstetrics and Gynecology, Faculty of Medicine, Toyama Medical and Pharmaceutical University

• KATSUMATA Noriyuki

  Department of Internal Medicine, National Cancer Institute

• TSUDA Hiroshi

  Department t of Obstetrics and Gynecology, Iiyama Red Cross Hospital

• UCHI Naoko

  Department of Obstetrics and Gynecology, Faculty of Medicine, Toyama Medical and Pharmaceutical University

• MIYAZAKI Satomi

  Department of Obstetrics and Gynecology, Faculty of Medicine, Toyama Medical and Pharmaceutical University

• HIDAKA Takao

  Department of Obstetrics and Gynecology, Faculty of Medicine, Toyama Medical and Pharmaceutical University

• SAKAI Masatoshi

  Department of Obstetrics and Gynecology, Faculty of Medicine, Toyama Medical and Pharmaceutical University

• SAITO Shigeru

  Department of Obstetrics and Gynecology, Faculty of Medicine, Toyama Medical and Pharmaceutical University

収録刊行物

• Japanese journal of cancer research : gann

  Japanese journal of cancer research : gann 93 (11), 1250-1257, 2002-11-30

キーワード

• Ovarian clear adenocarcinoma
• HER2
• Trastuzumab
• HERCEPTIN
• Growth inhibition

詳細情報

• CRID: 1572261550748276096
• NII論文ID: 50000703074
• NII書誌ID: AA00690844
• ISSN: 09105050
• Web Site: https://search.jamas.or.jp/link/ui/2003177808
• 本文言語コード: en
• データソース種別:
  • CiNii Articles